In this issue of Veterinary Pathology, Schott, Tatiersky, Foster, and Wood asked a specific question: How would 2 published grading schemes for canine osteosarcoma (OSA) perform when applied in real life? The answer for these appendicular OSA grading schemes was a resounding "not well." Why? There are multiple reasons these and some other grading schemes cannot be validated. As discussed in the article, factors include a lack of concordance between pathologists when assessing criteria in a grading scheme. 19 Factors that could prevent concordance include an absence of details of the methods employed in the original articles, an absence of standardized parameters used by pathologists, and the requirement for pathologists to make excessively subjective evaluations. Factors that create too much variation in the data can also prevent grading schemes from predicting outcome. For example, if the retrospective study spanned time periods with differences in diagnostic methods, stage of disease at enrollment, therapies, or accuracy of follow-up, then variation in survival and disease-free intervals across time might be expected. A lack of defined outcomes can also make it difficult for a scheme to predict prognosis. Outcomes in studies of companion animal cancer are strongly influenced by the values of pet owners, and the outcomes in many studies are unclear as the causes of death are not confirmed by autopsy. Many of these issues are problems in both human and veterinary oncology. However, their effects are amplified in cancer studies in pets because of the more limited clinical data that are often available, the higher variability in the treatments used, and personal factors such as beliefs, values, and finances that influence euthanasia decisions.
It has to be remembered that a grading scheme is useless unless it predicts the behavior of a neoplasm or guides therapeutic decisions. Currently, it is unclear which of the currently proposed grading systems for tumors in animals can provide useful prognostic information when applied to different populations of animals, owners, treatments, and pathologists. In human oncology, of 53 preclinical studies considered to be landmark, the results of only 11% could be confirmed in subsequent studies. 2 A lack of standardization regarding evaluation of tumors and the analysis of outcome data are significant impediments for validating grading schemes. If we want to compare the results between studies, we need to standardize parameters used by investigators (oncologists, biologists, pathologists) and describe the methods in such detail that they can be replicated. Results will not replicate exactly, but methods must.
It should also be noted that once a grading scheme has been proposed, typically using a limited number of cases, or with only one pathologist, it is important to collect further data that support its use in real-world settings. As pathologists, many of us have used grading schemes that have subsequently (often many years later) been found to be poorly predictive of behavior. Although the ability to predict behavior over a wider and more varied population is the most important function of a tumor grading scheme, there are typically few studies aimed at confirming or refuting the usefulness of a proposed grading scheme. 20 Schott et al 19 tried to accomplish this for OSA. Are we using the correct tools to predict behavior of cancers? Did the present authors choose the best grading schemes to apply to OSA? 11, 16, 18, 22 Are retrospective study designs too limited? Can medical records, as used in this study, be relied on to determine outcome assessment? Schott et al 19 provided some answers about OSA and generated questions applicable to other studies. Interested readers will find details provided in their text, figures, and supplemental tables. They designed a retrospective study of OSA and restricted cases to those with OSA in an appendicular location, those with no detectable metastases at entry, and those receiving 2 "standard of care" treatments intended for cure: amputation and chemotherapy. 19 Three pathologists used 2 published grading schemes to assess individual features and assign grades to 85 cases of OSA. 9, 12 Histologic sections were from amputated limbs, not core biopsies. The pathologists read the original manuscripts but were given no further instructions to evaluate histologic features or assign a grade; this design was intended to mimic how a diagnostic pathologist would apply published grading schemes. Outcome assessment was based on review of medical records and included median survival time (MST) and disease-free interval (DFI). A variety of statistical analyses including the conversion of data into 2-tier systems were used. Bottom line: histologic grade did not correlate with MST or DFI. For 1 of the 3 pathologists, increased number of mitotic figures in 3 random fields correlated with MST and DFI, which demonstrates the difficulty in applying histopathologic parameters consistently between pathologists. The authors concluded that "we need better tools to predict outcome of canine appendicular OSA." 19 This could be amended to "we need to identify the best test(s) to predict each cancer's behavior and standardize the parameters used for the evaluation of tumors and outcome assessments."
How accurate should predictions be, for a grading scheme to be useful? If a grading scheme predicts biologic behavior correctly for 90% of dogs with a tumor, that outcome has to be considered excellent. However, even then, we may not be able to predict those subsets that will not behave as predicted, and identifying these subsets could be important for an owner or oncologist. 10, 20 Would different sections from a large tumor yield the same grade? This is biology, and 100% accuracy is an unrealistic target.
We hope the findings of this study and others will stimulate discussions that lead to the formulation of standards for tumor evaluation in veterinary oncology. 27 A checklist of evaluated parameters should be created that could be used by investigators and reviewers of journals. These standards would include histologic features, ancillary tools, outcome assessment and the methods used for each. If we do not agree on how these parameters are evaluated, we will continue to create conflicting data 8, 21, 23, 24 and/ or different grading schemes for the same tumor. 7, 10, 19, 20 An international team of investigators, diagnosticians, and journal editors could create this document and keep it current. Our comments are directed primarily at microscopy and outcome assessment. However, standards are also needed for ancillary tools such as immunohistochemistry, flow cytometry, statistical analyses, 28 polymerase chain reaction for antigen receptor gene rearrangement (PARR), and other molecular techniques. 5, 8, 24, 26 If you agree with this principle, then there is no need to read more, as the following words just support the idea of standardization of our methods; the details for each technique are not included. We suspect that most individuals will agree that we need standardization. 27 But they will likely prefer their own methods to become the standard, and therefore agreement on which methods to use may be a hurdle that prevents the widespread adoption and advancement of standards.
Histologic Features
Schott et al 19 reported the histologic features and grading schemes for OSA had low concordance between pathologists, and they offered explanations. Histopathology and cytology are relatively inexpensive tests that provide diagnoses and can be used in grading schemes of many tumors in humans and animals. However, if grading schemes are to be widely applied, it is essential to use relevant microscopic features that are easily and objectively assessed, and that have distinct cutoffs, to ensure consistency among pathologists. Many grading schemes rely on vaguely defined cellular and histologic features such as differentiation or pleomorphism. There is usually good concordance between pathologists for determining low versus high grade; however, as intermediate grades are added, the distinguishing features are often blurred. 10 Without clear, simple methods to differentiate between grades, variation among pathologists increases, and there is a tendency for a high proportion of cases to be classified as intermediate grade. In addition, it has to be made clear whether pleomorphism should be assessed throughout the tumor or within the least or most differentiated parts. The difficulties in assessing these subjective criteria were well illustrated by Schott et al, 19 who reported that all 3 pathologists agreed on the same degree of pleomorphism in less than a quarter of neoplasms. If a grading system is to be applied more widely, it is essential to develop methods that allow a much greater concordance among pathologists in subjectively assessing the neoplastic cells.
Even when we are assessing objective measures, we have to ensure standardization. Counting mitotic figures in tumors is absolutely routine for pathologists and is the most common method to estimate cellular proliferation and predict outcomes. Mitotic count (MC) is used as an individual feature or as part of a grading scheme. 4, 10, 13, 25 However, even in this seemingly simple analysis, there is a lack of standardization, and it appears that not everyone is counting the same area within a high-power field. We believe that starting in an area of high cellularity near the periphery is where counting of mitotic figures should begin, but others might believe it is good to start at a random point. If so, experiments should be done to compare these approaches and agree on a standard protocol. Furthermore, we do not know the area that was counted in "ten HPFs" in almost all the existing publications that predicted tumor behavior. Schott et al 19 used MC and defined the area in 10 high-power fields as 2.37 mm 2 . All studies that enumerate mitotic figures need to use the proposed standardized area. 13 Therein could lie one of the problems, accepting and agreeing. If we do not standardize our methods, then we will continue to create inconsistent data. It is interesting to note in Schott et al's study that, although counting mitoses is such a routine analysis, there was variation among pathologists, as the MC correlated with MST and DFI for only 1 of the 3 pathologists.
Necrosis is also often included within proposed grading schemes. As with other parameters, it is critical is to define how necrosis is assessed. Original schemes for assessing necrosis in human neoplasms combined gross examination and histopathology. 4 ,25 Veterinary studies do not identify if only histopathology is used to assess necrosis; however, we believe that is how most of us assess this feature. Few diagnostic pathologists evaluate a gross specimen, and trimmers are typically instructed to avoid areas of necrosis and hemorrhage. The amount of necrosis present within a histological section of a neoplasm appears to be dependent, at least partially, on how well the trimmer was able to identify, and avoid, necrosis within the tumor. Therefore, it seems the methods used to identify or avoid necrosis could be quite variable between studies. As with other criteria, it is essential that methods are standardized and fully described so experiments can be repeated and the results compared. We believe it is likely that necrosis will be abandoned as a criterion for tumor grading as new data emerge that determine its usefulness and or subjectivity.
Parameters should be assessed as objectively as possible, and the more definitively the feature can be defined, the more consistent the assigned "number" will be, but in reality, the pathologist has to make judgment calls on individual features and/or an overall assessment. This is a component of our specialty that challenges us. Perhaps a category could be added to a future study: the pathologist's assessment of this neoplasm is __________. Have we undermined this editorial by stating the opinion of the pathologist still has value? We are certain lawyers will want to see these data. Sarcasm aside, the pathologists' subjective assessment based on what they see and they have experienced in their careers is important, especially for tumors in which grades, MC, or molecular profiles have not been correlated with outcome assessments. The younger generation of internists wants another test that directs therapy or their diagnosis. There is no single test that is 100% reliable; biology will produce exceptions, and the integration of all the data is still the responsibility of a thinking mind.
Pathology is our specialty, it is our responsibility to standardize histologic and or cytologic features that should be evaluated and to standardize how they are evaluated: mitotic figures, MCs, necrosis, degree of differentiation, pleomorphisim of cells and nuclei, margins, size. 27 Studies need to evaluate numerous individual or combined features but then reduce these to the minimum needed to predict outcome. Histology and cytology are affordable for most pet owners. They will remain as the gold standard for diagnoses of tumors, and when they provide prognostic or predictive information that has been validated, they will be essential aids for veterinary oncology. New parameters, new grading schemes, and molecular markers need to be introduced and validated but not as standalone additions. 5, 8, 17, 24 Molecular tools and artificial intelligence have been coming to a laboratory near us for a long time. We welcome them, they have great potential, and they should be a part of new investigations. They will be more useful if they are compared with light microscopic features that owners can afford and that we all can evaluate at our microscopes or video screens. 3, 15 Diagnostic centers will perform the more esoteric tests if they are predictive/prognostic. Eventually, tests may predict outcome and treatment recommendations for an individual animal and tumor, particularly as targeted therapeutics make their way into veterinary oncology.
Outcome Assessment
Schott et al 19 suggested that grading schemes based solely on microscopic features may not be sufficiently predictive, and other techniques (such as molecular methods) may be needed to predict the outcome of appendicular OSA. Other studies have similarly indicated that tumor staging and new tests may be necessary to predict clinical behavior. But how do we determine which tests are predictive and or prognostic? The answer is effective outcome assessment. Outcome assessment determines if a test was predictive of a treatment or prognostic of tumor behavior. These data need to be collected as carefully and accurately as the techniques used to assess tumors. It takes years to accumulate cases, and during this time, clinicians and treatments may change, end-of-life decisions may vary, and medical records may not be complete. Schott et al analyzed specific histopathology data from 3 pathologists, yet endpoints were determined by multiple clinicians, radiologists, and caregivers over a 17-year period. The poor concordance between pathologists suggested that histopathology is too imprecise a tool to predict the behavior of a tumor as aggressive as OSA; however, did the variability in treatments and outcome assessments also significantly contribute to the weak predictability of the schemes?
In contrast to our human pathology colleagues, determining a detailed clinical history and an accurate outcome is much more difficult and subjective in veterinary medicine. Anyone who has tried to develop a large data set of outcomes of any particular tumor type will know that it is often very difficult to contact owners and obtain accurate follow-up data. In fact, if investigators were able to accumulate a large accurate database of outcomes for a particular neoplasm, many other researchers would clamor to apply their molecular, immunohistochemical, MC, and automated systems to that tumor. Techniques are relatively easy to apply, but collecting objective and accurate outcomes is not (RESIST, PERSIST, CASA). 6, 14 Endpoints in toxicologic risk studies are well defined, but this is not so well defined for our studies with pets. Decisions to euthanize a pet are personal, and those decisions affect outcomes. Might survival time and DFI be different for dogs with the same tumor, if owners have different values of life and the role of pets in their family? Might Kaplan-Meier survival functions be different for dogs in high versus low median income households? People who take their animals to be treated at veterinary referral centers are likely to be much more motivated to prolong treatments and therefore survival of their pets. If the neoplasm usually results in euthanasia due to local recurrence, clients at referral centers may be more likely to request repeated surgeries than clients of general practitioners. If this is true, then will a tumor grading system that was developed using tumors on pets at a referral center be able to predict the survival of animals seen by general practitioners? Subjective factors influence euthanasia, but we would like objective information on the biologic behavior of the tumor, and autopsies are a way to determine the biologic behavior. 26 We need more autopsies in cancer studies, because the autopsy confirms or refutes clinical suspicions. An autopsy also identifies concurrent diseases and provides light microscopic confirmation to determine if the same tumor is in the metastasis or recurrence site. If the words confirmed recurrence or confirmed metastasis are used in a publication, then those terms should be reserved for light microscopic confirmation that the same tumor is in both the primary tumor and in metastases. Imaging is a powerful diagnostic tool, but it cannot confirm the same tumor is in the metastasis. Tumor collision is rare, but the occurrence of 2 malignant tumors in the same dog is well characterized and fits with genetic susceptibility to cancer. Data presented in the article (even in supplemental tables) should distinguish between metastases identified by imaging versus metastases confirmed by histopathology. The number of cases in our cancer studies with autopsy data is abysmal. Authors should report how many of the cases had an autopsy. Full data sets should be required by the journal so that others can scrutinize or apply their own statistical models.
Accurate outcome assessments are also used to change grades or diagnoses or identify subtypes of a tumor. If a tumor is histologically designated as malignant (aggressive) or benign but follow-up data indicate that prediction was incorrect, then changes need to be made in the grading or diagnostic terms. This type of long-term follow-up has resulted in changes for the prognoses and diagnoses for tumors in human oncology. Are all histiocytomas benign? Are all soft-tissue sarcomas malignant? Perivascular wall tumors are part of this generic group of mesenchymal tumors, yet as a subset, they are not aggressive. 1 Tumors may appear identical microscopically, but additional tests identify subsets. 5, 17 These subsets identified by molecular tests or other methods need accurate long-term follow-up to know if the test provided clinically useful information to direct treatments or provide prognoses.
In conclusion, standardizing grading schemes to a level of detail that allows wide implementation will be a challenging but necessary process. Likewise, it is essential to standardize outcome assessment during the development of the scheme and subsequently when the proposed scheme is validated in "real life" situations. Without appropriate validation, grading schemes should not be widely adopted and used to provide prognoses or direct clinical therapy. It is hard to know how to implement suggested changes, although forming a group and creating a working document may be the starting point. Consensus statements on this idea are not new; getting individuals or journals to agree and follow guidelines would be new. 27 It is unknown who would administer such a document, but perhaps Schott et al 19 and others have stimulated the editors of pathology and oncology journals to accept this challenge. If they do, it should lead to better patient care.
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